FDA To Share Perspective On Polymorphic Forms In Abbreviated New Drug Applications - 6th Annual IQPC Polymorphism & Crystallisation Conference

Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Pharmacy / Pharmacist;  Pharma Industry / Biotech Industry
Article Date: 23 Nov 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:1 star

1 (1 votes)

Healthcare Prof:not yet rated


The FDA have confirmed they will be providing an insight into Polymorphic Forms in Abbreviated New Drug Applications (ANDAs).

Andre Raw, Ph.D, Senior Regulatory Chemist at the Office of Generic Drugs, based at the Centre of Drug Evaluation and Research (CDER) will be delivering the information via a presentation at the 6th annual IQPC Polymorphism & Crystallisation conference which takes place 11-13th March 2009 in London.

Dr. Raw will address the scientific considerations of polymorphism to drug product safety, efficacy and quality; as well as those considerations of polymorphism applicable to drug product formulation and process design.

Delegates will be provided with an overview of regulatory considerations of polymorphism in ANDA's as well as looking in more detail at question based review and interlinking regulatory considerations of polymorphism to pharmaceutical Quality by Design in ANDAs.

Sarah Haynes, Event Director at Pharma IQ responded to the confirmation saying "This is a great opportunity for the FDA to answer the attendees' most important questions. Having an official onsite is a rarity at any European conference and I am sure that this will make for interesting and varied discussion. It will certainly help support the event's aim to allow participants to take home essential practical advice and guidance."

IQPC has an established reputation for delivering the highest standard of industry specific conferences, seminars and internal training programmes. We aim to keep business executives up-to date with the forefront of their industries' trends, technological developments and regulatory landscape.

http://www.iqpc.co.uk

Article adapted by Medical News Today from original press release.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
IQPC. "FDA To Share Perspective On Polymorphic Forms In Abbreviated New Drug Applications - 6th Annual IQPC Polymorphism & Crystallisation Conference." Medical News Today. MediLexicon, Intl., 23 Nov. 2008. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/130380.php>

APA
IQPC. (2008, November 23). "FDA To Share Perspective On Polymorphic Forms In Abbreviated New Drug Applications - 6th Annual IQPC Polymorphism & Crystallisation Conference." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/130380.php.

Please note: If no author information is provided, the source is cited instead.


Regulatory Affairs / Drug Approvals

Most Popular Articles



Follow Our Regulatory Affairs News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Regulatory Affairs / Drug Approvals Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »